NASDAQ:GRFS
Grifols Stock News
$6.57
+0.180 (+2.82%)
At Close: May 03, 2024
BARCELONA, Spain, April 2, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years
BARCELONA, Spain, March 9, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the h
Moving Average Crossover Alert: Grifols
08:21am, Monday, 08'th Mar 2021
Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Is Grifols (GRFS) a Great Value Stock Right Now?
12:51pm, Thursday, 04'th Feb 2021
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
GRFS vs. ZTS: Which Stock Is the Better Value Option?
12:52pm, Wednesday, 03'rd Feb 2021
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19
06:00am, Monday, 18'th Jan 2021
BARCELONA, Spain, Jan. 18, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more t
GRFS or ZTS: Which Is the Better Value Stock Right Now?
12:48pm, Tuesday, 12'th Jan 2021
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing
02:07pm, Sunday, 03'rd Jan 2021
Good prospects for the global immunoglobulin business. Koru Medical's strategic plan is to reach $ 50M in sales by 2022, a gross margin of 70%, and organic and annual sales growth of + 20%.
The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies
09:14am, Monday, 16'th Nov 2020
BARCELONA, Spain, Nov. 16, 2020 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with mo
Grifols Class B: Buy The Recovery In The U.S. Plasma Business
08:00am, Wednesday, 11'th Nov 2020
Oligopoly of four companies that control more than 80% of the plasma business. Secular growth trend for population aging.
Grifols Looks Enticing After Big Sell-Off In Spain
01:07am, Friday, 30'th Oct 2020
The Spanish market has gotten crushed with an uptick in COVID-19 deaths. Grifols stock is about where it was when I visited headquarters three years ago.
CSL Limited: A Twindemic Can Unravel A Pricey Premium
11:43am, Sunday, 13'th Sep 2020
The pandemic-related lockdowns have dried up CSL’s plasma supplies, though a possible flu outbreak can accelerate the influenza vaccine sales and offset the impact of a slowdown in plasma-derived pr
Tracking George Soros's Portfolio - Q2 2020 Update
01:21pm, Friday, 21'st Aug 2020
Soros' 13F portfolio value increased from $1.98B to $4.48B this quarter. The number of positions increased from 118 to 141.
ICU Medical Inc. (NASDAQ: ICUI) today announced that it has entered into a long-term agreement with Grifols to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injecti
Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study
10:04pm, Wednesday, 05'th Aug 2020
The results provide more justification for the FDA to grant the substance emergency use authorization.
